Liquidia signs Vectura license: $2M upfront, up to $92.5M

Liquidia Corporation entered an exclusive license with Vectura Limited to develop, manufacture and commercialize in the United States treprostinil products, including Liquidia’s L606, administered via Vectura’s nebulizer device for PAH and PH‑ILD.

Rhea-AI Filing Summary

Liquidia Corporation entered an exclusive license with Vectura Limited to develop, manufacture and commercialize in the United States treprostinil products, including Liquidia’s L606, administered via Vectura’s nebulizer device for PAH and PH‑ILD. Vectura will manufacture and supply clinical and commercial devices.

Financial terms include an upfront $2,000,000 payment, development milestones of up to $12,000,000, sales milestones of up to $92.5 million, and royalties at middle single‑digit rates on U.S. sales. Liquidia also secured rights of first negotiation for additional territories and indications. The agreement continues on a country‑ and product‑specific basis through the applicable royalty term and includes customary termination rights for breach, bankruptcy, program discontinuation, feasibility determinations, related agreement terminations, effort requirements, and patent challenges.

Insights

Biopharma licensing analyst

Exclusive Vectura license adds device pathway; cash costs are milestone‑weighted.

Liquidia gains U.S. rights to pair treprostinil, including L606, with Vectura’s nebulizer, while Vectura supplies clinical and commercial devices. This aligns drug and device under one framework, clarifying responsibilities and enabling a defined commercial route in PAH and PH‑ILD.

Economics include an upfront $2,000,000, development milestones up to $12,000,000, sales milestones up to $92.5 million, and royalties in the middle single digits. Payments are contingent on milestones and sales performance, which helps stage cash outflows but adds dependency on program progress and market uptake.

Key dependencies include regulatory success for L606 and sustained device supply by Vectura. Termination clauses cover program discontinuation, effort requirements, and patent challenges. Subsequent filings may provide timing for development milestones and commercialization steps.

8-K Event Classification

2 items: 1.01, 9.01

2 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What agreement did LQDA sign with Vectura?

An exclusive U.S. license to develop, manufacture and commercialize treprostinil products, including L606, using Vectura’s nebulizer device.

What upfront and milestone payments are in the Liquidia–Vectura deal?

Upfront payment is $2,000,000, with development milestones up to $12,000,000 and sales milestones up to $92.5 million.

What royalty terms are disclosed for LQDA under the license?

Royalty rates are described as in the middle single digits on U.S. commercial sales.

Who supplies the device for Liquidia’s L606 program?

Vectura will manufacture and supply clinical and commercial quantities of its nebulizer device.

What diseases are targeted under the license?

Pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH‑ILD), within hypertension and interstitial lung diseases.

Does the license cover territories outside the U.S.?

The license grants U.S. rights and gives Liquidia rights of first negotiation to add additional territories and indications.

What are key termination rights in the agreement?

Termination may occur for mutual agreement, material breach, bankruptcy events, L606 discontinuation, feasibility determinations, related agreement terminations, effort failures, or patent challenges.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/30/2025 - 07:00 AM Learn about SEC filing dates

false 0001819576 0001819576 2025-10-27 2025-10-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 27, 2025

LIQUIDIA CORPORATION
(Exact name of registrant as specified in its charter)
Delaware	001-39724	85-1710962
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

419 Davis Drive, Suite 100, Morrisville, North Carolina	27560
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (919) 328-4400 

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock	LQDA	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 1.01 Entry Into a Material Definitive Agreement.

On October 27, 2025 (the “Effective Date”), Liquidia Technologies, Inc., a Delaware corporation (“Liquidia Technologies”) and a wholly owned subsidiary of Liquidia Corporation, a Delaware corporation (the “Company”), entered into an exclusive licensing agreement (the “License Agreement”) with Vectura Limited, a company incorporated under the laws of England and Wales (“Vectura”), which provided for, among other things, (i) the exclusive right for Liquidia Technologies to develop, manufacture and commercialize for use in the United States (the “Territory”) products containing treprostinil, including Liquidia Technologies’ L606, administered via Vectura’s nebulizer device (the “Device”) for treatment in the field of hypertension and interstitial lung diseases, including pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) and (ii) that Vectura shall be responsible for manufacturing and supplying Liquidia Technologies with clinical and commercial supplies of the Device.

Under the License Agreement, Liquidia Technologies shall pay to Vectura (i) an upfront payment of $2,000,000 in connection with the execution of the License Agreement, (ii) certain development milestone payments of up to $12,000,000 upon achievement of certain development milestones; (iii) certain sales milestone payments of up to $92.5 million tied to commercial sales in the Territory and (iv) royalty payments with royalty rates ranging in the middle single digits tied to commercial sales in the Territory. The License Agreement also provides Liquidia Technologies with rights of first negotiation to add additional territories and indications during the term thereof as set out in the License Agreement.

The License Agreement is effective upon the Effective Date and unless earlier terminated, shall remain in effect on a country-by-country and product-by-product basis until the expiration of the applicable Royalty Term (as defined in the License Agreement) in such country with respect to such product, at which time the License Agreement shall expire in respect of such country and product. The License Agreement may be terminated (i) by mutual agreement, (ii) by either party for a material breach by the other party, subject to notice and cure periods, (iii) by either party in the event of a Bankruptcy Event (as defined in the License Agreement) of the other party, (iv) by Liquidia Technology in the event it (x) discontinues the L606 program, (y) determines regulatory, scientific or technical infeasibility or (z) terminates its related supply or development agreements, and (v) by Vectura for (x) Liquidia Technology’s failure to use commercially reasonable efforts to develop a product under the License Agreement, (y) upon receipt of notice that Liquidia Technologies will discontinue the L606 program or (z) in the event that Liquidia Technologies initiates a challenge to Vectura’s patent rights being licensed under the License Agreement.

The foregoing description of the terms of the License Agreement is not complete and is qualified in its entirety by reference to the text of the License Agreement, which will be filed as an exhibit to the Company’s Annual Report on Form 10-K for the fiscal year ending December 31, 2025.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Exhibit
104		Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

October 30, 2025	Liquidia Corporation
	By:	/s/ Michael Kaseta
		Name:	Michael Kaseta
		Title:	Chief Financial Officer and Chief Operating Officer